Company intelligence / Profile preview

SyncThink

Palo Alto, California, USAneurosync.health ↗

Ownership: Private
Development stage: Commercial

Overview

The EYE-SYNC platform has demonstrated sensitivity above 82% and specificity above 93% for concussion diagnosis in a clinical study of over 1,600 subjects. It provides rapid (<60 seconds), objective eye-tracking assessments to aid clinicians in diagnosing concussion/mTBI. The technology has received FDA clearance as an aid to concussion diagnosis and CE mark approval for broader neurological assessment.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (digital diagnostics and digital therapeutics)Artificial intelligence-based software
Industry: Digital Health Medical Devices

Partnerships

Magic Leap (AR hardware collaboration)

Beyond the preview

Go deeper on SyncThink.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SyncThink.

Explore the full profile